My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Jazz Pharmaceuticals plc - Ordinary Shares (NQ:JAZZ)

129.59 +0.19 (+0.15%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Jazz Pharmaceuticals plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Assessing Jazz Pharmaceuticals: Insights From 7 Financial Analysts
 
Via Benzinga
7 Biotech Stocks to Boost Your Portfolio to Peak Health
With biotech stocks commanding a permanently relevant narrative, you can’t afford to ignore these highly endorsed ideas. 
Via InvestorPlace
3 Cannabis Stocks That Could Make Your Grandchildren Rich
These cannabis stocks offer long-term growth potential anchored by solid operational models and diversified revenue streams today. 
Via InvestorPlace
Topics Cannabis
Why Is Jazz Pharmaceuticals Stock Trading Lower On Thursday?
Jazz Pharmaceuticals announced Phase 2b trial results for suvecaltamide (JZP385) in essential tremor patients, revealing no significant improvements over placebo. 
Via Benzinga
Jazz Dives — And Takes Praxis With It — On Essential Tremor Drug Failure
The companies are working on treatments for essential tremor, a tricky indication. 
Via Investor's Business Daily
3 Blue-Chip Stocks to Triple Your Wealth by 2026: June Edition
These blue-chip stocks offer stability, sustainable growth and operational models less prone to wider economic fluctuations. 
Via InvestorPlace
Decoding 12 Analyst Evaluations For Jazz Pharmaceuticals
 
Via Benzinga
Demystifying Jazz Pharmaceuticals: Insights From 15 Analyst Reviews
 
Via Benzinga
Breaking Down Jazz Pharmaceuticals: 15 Analysts Share Their Views
 
Via Benzinga
This Old Dominion Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
 
Via Benzinga
7 Overlooked Stocks Offering Long-Term Stability From the Shadows
These overlooked stocks offer price appreciation, income, and more while diversifying across sectors and company sizes. 
Via InvestorPlace
3 Cannabis Stocks to Buy Now: May 2024
These cannabis stocks to buy offer the best odds at capturing long-term upside from current rescheduling initiatives. 
Via InvestorPlace
Topics Cannabis
7 Blue-Chip Stocks to Buy Now: May 2024
These blue-chip stocks to buy offer long-term price appreciation opportunities reinforced with undeniable stock stability. 
Via InvestorPlace
Cannabis Meets Prescription Drugs, Steroids And Ketamine In Schedule III: What It Means, Key Stocks To Watch
President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA). 
Via Benzinga
Topics Cannabis
The Analyst Landscape: 12 Takes On Jazz Pharmaceuticals
 
Via Benzinga
Demystifying Jazz Pharmaceuticals: Insights From 4 Analyst Reviews
 
Via Benzinga
3 Cheap Blue-Chip Stocks to Buy Now: May 2024
If stock market speculation isn't quite working in your favor, these cheap blue-chip stocks may be the boost your portfolio needs. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In
Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028. 
Via Benzinga
Topics Cannabis
7 Cannabis Stocks to Buy for a Smoking-Hot 2024
Ignite your portfolio with these seven sizzling cannabis stocks. From industry leaders to innovative upstarts. 
Via InvestorPlace
Topics Cannabis
The 7 Top-Selling Cannabis Companies Ranked by Revenue: Which Weed Stocks to Buy?
These top cannabis stocks by revenue are among the world's best sellers, making them prime investment opportunities to capture legal changes. 
Via InvestorPlace
Topics Cannabis
JAZZ Stock Earnings: Jazz Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024
JAZZ stock results show that Jazz Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
3 No-Brainer Stocks to Buy With $300 Right Now
A modest amount of money can go a long way on Wall Street when it's put to work in time-tested businesses with well-defined catalysts. 
Via The Motley Fool
How To Make Your Cannabis Business More Attractive For Investors In 2024: Advice On Financial Health & Innovation
 
Via Benzinga
Topics Cannabis
HC Wainwright & Co. Maintains Buy Rating for Jazz Pharmaceuticals: Here's What You Need To Know
 
Via Benzinga
7 Biotech Stocks to Buy as Sector Rotation Ramps Up
With digital innovation possibly getting overextended, now’s the time to consider biotech stocks for an incoming rotation. 
Via InvestorPlace
Time Is Still The Enemy, Says Mom Who Moved Mountains For Her Epileptic Daughter & Still Advocates For Millions Of CBD Users
 
Via Benzinga
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
Although the health innovation space can be a risky environment, undervalued biotech stocks can take some of the edge off. 
Via InvestorPlace
4 Exhilarating Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
The Nasdaq Composite is the only major stock index that hasn't put the 2022 bear market in the rearview mirror. For patient investors, it means bargains still abound. 
Via The Motley Fool
Topics Stocks
3 Cannabis Stocks That Could Be Multibaggers in the Making: February Edition
Don’t miss out, as the following cannabis stocks are severely undervalued and are set to increase sales and make huge profits in 2024. 
Via InvestorPlace
Topics Cannabis
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.